EDP-235

DRUG4 trials

Sponsors

Enanta Pharmaceuticals, Inc

Conditions

COVID-19SARS CoV 2 Infection

Phase 1

A Study of EDP-235 in Healthy Subjects

CompletedNCT05246878

Enanta Pharmaceuticals, IncSARS CoV 2 Infection

Start: 2022-01-28End: 2022-07-20Updated: 2022-08-19

Drug-Drug Interaction Study Between EDP-235, Midazolam, Caffeine and Rosuvastatin in Healthy Subjects

CompletedNCT05594615

Enanta Pharmaceuticals, IncCOVID-19

Start: 2022-10-06End: 2022-11-18Updated: 2023-04-27

Drug-Drug Interaction Study Between EDP-235, Itraconazole, Carbamazepine and Quinidine in Healthy Subjects.

CompletedNCT05594602

Enanta Pharmaceuticals, IncCOVID-19

Start: 2022-10-06End: 2022-12-30Updated: 2023-04-27

Phase 2

A Study to Evaluate EDP-235 in Non-hospitalized Adults With COVID-19

CompletedNCT05616728

Enanta Pharmaceuticals, IncCOVID-19

Start: 2022-11-10End: 2023-06-29Updated: 2024-08-19